Physician profile
Brian Hiller
NPI 1386978104
$6,974.13
in general payments reported to CMS, 2019-2025
48 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $570 · 2023: $1,322 · 2024: $2,111 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,799 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,799.04 |
| Education | $113.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.00 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $850.63 | 2023-2025 | |
| Amgen INC. | $617.31 | 2021-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $556.06 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $330.17 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $297.38 | 2021-2025 | Mounjaro, Emgality, Reyvow |
| Pfizer INC. | $238.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.30 | 2023-2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $205.02 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.66 | 2021-2025 | Jardiance |
| Genzyme Corporation | $162.54 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $149.70 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $142.55 | 2023-2025 | Dupixent |
| Vanda Pharmaceuticals INC. | $128.95 | 2024-2025 | Fanapt |
| Antares Pharma, INC. | $119.34 | 2021-2024 | Xyosted |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $107.81 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $92.23 | 2021-2023 | Xarelto |
| Horizon Therapeutics Plc | $79.20 | 2021 | |
| Organon LLC | $76.05 | 2022-2025 | Vtama |
| Esperion Therapeutics, INC. | $71.35 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $58.84 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.97 | 2023-2025 | Xifaxan, Trulance |
| Halozyme INC | $56.66 | 2023 | |
| Dexcom, INC. | $56.41 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $51.10 | 2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $45.11 | 2024 | Yupelri |
| Astellas Pharma US INC | $45.00 | 2024 | Veozah |
| Ars Pharmaceuticals Operations, INC. | $41.79 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $40.97 | 2022-2023 | Arexvy, Shingrix |
| Hologic Sales and Service, LLC | $39.87 | 2022-2023 | Thinprep 2000 Processor |
| Alk-Abello, INC | $39.75 | 2023-2024 | Ragwitek, Odactra, Grastek |
| Axsome Therapeutics, INC. | $32.14 | 2024 | Auvelity |
| Allergan, INC. | $29.99 | 2021 | |
| Merck Sharp & Dohme LLC | $29.17 | 2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.83 | 2022 | |
| Viatris Specialty LLC | $27.70 | 2025 | Yupelri |
| Verity Pharmaceuticals INC. | $27.45 | 2025 | Tlando |
| Itamar Medical INC | $26.73 | 2025 | Watchpatone |
| Ascensia Diabetes Care US INC. | $23.62 | 2024 | |
| Sanofi Pasteur INC. | $23.04 | 2023 | |
| Cleerly, INC. | $21.77 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Exact Sciences Corporation | $20.96 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $20.48 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.92 | 2021 | |
| Edwards Lifesciences Corporation | $19.19 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bardy Diagnostics, INC. | $18.29 | 2021 | |
| Clarus Therapeutics INC. | $16.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.